Exelixis (EXEL)

NASDAQHealth CareBiotechnologySnapshot 2026-10-23

$64.53-1.19%

Close 2026-10-23 · 1-day change

Investment OutlookAs of Oct 24, 2026

What could strengthen or challenge Exelixis’s outlook?

The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.

Higher potential upsideImproving expectations

Next-FY EPS estimate change · 30 days

+1.2%

+10% or more+5%0%−5%−10% or less

4.15 → 4.20 EPS · FY ending Jan 2, 2028 · 9 analysts

Higher risk of downsideWeakening expectations

One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.

How this is measured

Change in the same fiscal period’s mean EPS estimate from Sep 24, 2026 to Oct 24, 2026: (new ÷ prior − 1). Contributor count changed from 9 to 9; this is not the number of analysts revising. Source: FMP consensus snapshots. The ±10% axis is a display range.

Measure / period	Management expectations	Analyst expectations
FY 2026 · Q4
Revenue	—	663.25M
EPS	—	0.869
FY 2026 · Annual
product revenue	$2.3B–$2.35B	—
Revenue	$2.5B–$2.55B	2.55B
EPS	—	3.563
R&D	$825M–$875M	—
FY 2027 · Annual
Revenue	—	2.9B
EPS	—	4.196

What the Thesis Depends On

Three published thesis conditions, with dated milestones shown separately.

Key Factor	Why It Matters	Current Status	Break Condition	Latest Evidence
Complete $750 million stock repurchase by end 2027	The company is buying back $750 million in stock, showing strong capital return.	Intact	Buyback program is canceled or materially reduced	Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
Increase operating income to at least $251 million in Q1 2026	Profit rises with operating income hitting $251 million in Q1 2026.	Intact	Operating income falls below $187 million in Q1 2026	Operating income: $248.414M FY2026-Q2; GAAP. Published target: >= $251 million. The stored target says 2026-Q1; this source reports FY2026-Q2. Fiscal/calendar alignment needs review. Source published Aug 5, 2026248,414,000 USD · source valueSource reportLast status assessment Oct 24, 2026 Measurement source consolidated · GAAP FY2026-Q2 · Period ending Jul 3, 2026 Source: company_financial_results. Reference: e341783a-cdb3-48b0-b60c-d69a0b348bb9. Source status: eligible. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
Maintain revenue near $2.575 billion in FY26	A primary condition in Exelixis's published investment case. The stated target is ~$2.575 billion.	Intact	Revenue falls below $2.3 billion in FY26	Revenue: $628.69M FY2026-Q2; GAAP. Published target: ~$2.575 billion. Target period is not explicitly aligned with this observation. Source published Aug 5, 2026628,690,000 USD · source valueSource reportLast status assessment Oct 24, 2026 Measurement source consolidated · GAAP FY2026-Q2 · Period ending Jul 3, 2026 Source: company_financial_results. Reference: e341783a-cdb3-48b0-b60c-d69a0b348bb9. Source status: eligible. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.

Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.

Incoming Evidence

Compare these dated observations with the operating requirements above

Expectations trend

Same fiscal period

FY2028 · fiscal year ending 2028-01-02 · fmp

FY2028 EPS$4.20

$3.97 → $4.20 · observed estimates

FY2028 revenue$2.90B

$2.93B → $2.90B · observed estimates

Exact estimates & source dates

One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.

FY2028 estimate observations · fmp
Snapshot	EPS	Revenue	EPS / revenue analysts
2026-07-24	$3.97	$2,933,512,960	10 / 12
2026-07-25	$3.97	$2,933,512,960	10 / 12
2026-07-26	$4.09	$2,932,479,114	10 / 12
2026-07-27	$4.09	$2,932,479,114	10 / 12
2026-07-28	$4.09	$2,932,479,114	10 / 12
2026-07-29	$4.09	$2,932,479,114	10 / 12
2026-07-30	$4.09	$2,932,479,114	10 / 12
2026-07-31	$4.09	$2,932,479,114	10 / 12
2026-08-01	$4.09	$2,932,479,114	10 / 12
2026-08-02	$4.09	$2,932,462,961	10 / 12
2026-08-03	$4.09	$2,932,462,961	10 / 12
2026-08-04	$4.09	$2,932,462,961	10 / 12
2026-08-05	$4.09	$2,932,462,961	10 / 12
2026-08-06	$4.09	$2,932,462,961	10 / 12
2026-08-07	$4.06	$2,886,345,253	9 / 12
2026-08-08	$4.06	$2,886,345,253	9 / 12
2026-08-09	$4.06	$2,886,345,253	9 / 12
2026-08-10	$4.06	$2,886,345,253	9 / 12
2026-08-11	$4.06	$2,886,345,253	9 / 12
2026-08-12	$4.06	$2,886,345,253	9 / 12
2026-08-13	$4.06	$2,886,345,253	9 / 12
2026-08-14	$4.06	$2,886,345,253	9 / 12
2026-08-15	$4.06	$2,886,345,253	9 / 12
2026-08-16	$4.06	$2,886,345,253	9 / 12
2026-08-17	$4.06	$2,886,345,253	9 / 12
2026-08-18	$4.06	$2,886,345,253	9 / 12
2026-08-19	$4.06	$2,886,345,253	9 / 12
2026-08-20	$4.01	$2,864,340,282	10 / 13
2026-08-21	$4.01	$2,864,340,282	10 / 13
2026-08-22	$4.01	$2,864,340,282	10 / 13
2026-08-23	$4.01	$2,864,340,282	10 / 13
2026-08-24	$4.01	$2,864,340,282	10 / 13
2026-08-25	$4.01	$2,864,340,282	10 / 13
2026-08-26	$4.01	$2,864,340,282	10 / 13
2026-08-27	$4.01	$2,864,340,282	10 / 13
2026-08-28	$4.01	$2,864,340,282	10 / 13
2026-08-29	$4.08	$2,864,351,393	10 / 13
2026-08-30	$4.15	$2,894,148,534	10 / 13
2026-08-31	$4.15	$2,894,148,534	10 / 13
2026-09-01	$4.15	$2,894,148,534	10 / 13
2026-09-02	$4.15	$2,894,172,063	10 / 13
2026-09-03	$4.15	$2,894,307,357	9 / 13
2026-09-04	$4.15	$2,894,307,357	9 / 13
2026-09-05	$4.15	$2,894,307,357	9 / 13
2026-09-06	$4.15	$2,894,307,357	9 / 13
2026-09-07	$4.15	$2,894,307,357	9 / 13
2026-09-08	$4.15	$2,894,307,357	9 / 13
2026-09-09	$4.15	$2,894,307,357	9 / 13
2026-09-10	$4.15	$2,894,307,357	9 / 13
2026-09-11	$4.15	$2,894,307,357	9 / 13
2026-09-12	$4.12	$2,894,303,936	9 / 13
2026-09-13	$4.12	$2,894,303,936	9 / 13
2026-09-14	$4.12	$2,894,303,936	9 / 13
2026-09-15	$4.15	$2,894,303,936	9 / 13
2026-09-16	$4.15	$2,894,303,936	9 / 13
2026-09-17	$4.15	$2,894,303,936	9 / 13
2026-09-18	$4.15	$2,894,303,936	9 / 13
2026-09-19	$4.15	$2,894,303,936	9 / 13
2026-09-20	$4.15	$2,894,303,936	9 / 13
2026-09-21	$4.15	$2,894,303,936	9 / 13
2026-09-22	$4.15	$2,894,303,936	9 / 13
2026-09-23	$4.15	$2,894,303,936	9 / 13
2026-09-24	$4.15	$2,894,303,936	9 / 13
2026-09-25	$4.15	$2,894,303,936	9 / 13
2026-09-26	$4.15	$2,894,303,936	9 / 13
2026-09-27	$4.15	$2,894,303,936	9 / 13
2026-09-28	$4.15	$2,894,303,936	9 / 13
2026-09-29	$4.15	$2,894,303,936	9 / 13
2026-09-30	$4.15	$2,894,303,936	9 / 13
2026-10-01	$4.13	$2,900,135,432	9 / 12
2026-10-02	$4.13	$2,900,136,945	9 / 12
2026-10-03	$4.13	$2,900,136,945	9 / 12
2026-10-04	$4.13	$2,900,136,945	9 / 12
2026-10-05	$4.13	$2,900,136,945	9 / 12
2026-10-06	$4.12	$2,890,211,945	9 / 12
2026-10-07	$4.12	$2,892,856,736	9 / 12
2026-10-08	$4.12	$2,892,602,392	9 / 12
2026-10-09	$4.12	$2,890,914,892	9 / 12
2026-10-10	$4.12	$2,890,914,892	9 / 12
2026-10-11	$4.15	$2,895,288,212	9 / 12
2026-10-12	$4.15	$2,895,288,212	9 / 12
2026-10-13	$4.15	$2,895,288,212	9 / 12
2026-10-14	$4.14	$2,895,288,212	9 / 12
2026-10-15	$4.11	$2,895,288,212	9 / 12
2026-10-16	$4.11	$2,895,288,212	9 / 12
2026-10-17	$4.11	$2,895,288,212	9 / 12
2026-10-18	$4.11	$2,895,288,212	9 / 12
2026-10-19	$4.11	$2,895,288,212	9 / 12
2026-10-20	$4.20	$2,895,288,212	9 / 12
2026-10-21	$4.20	$2,899,400,712	9 / 12
2026-10-22	$4.20	$2,899,400,712	9 / 12
2026-10-23	$4.20	$2,899,400,712	9 / 12
2026-10-24	$4.20	$2,899,400,712	9 / 12

Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.

Compare required revenue and earnings

Analyst view

Monthly observations

Buy / Strong BuyHoldSell / Strong Sell

Exact monthly counts

Monthly rating snapshots · fmp. Missing snapshots are not zero.
Date	Buy*	Hold	Sell*
2026-05-01	10	9	1
2026-06-01	10	10	1
2026-07-01	8	10	1
2026-08-01	8	12	1
2026-09-01	7	12	1
2026-10-01	7	10	1

*Buy includes Strong Buy; Sell includes Strong Sell. Monthly counts describe the analyst mix, not the firms behind each recent action.

Latest: 7 Buy / Strong Buy · 10 Hold · 1 Sell / Strong Sell

0 upgrades0 downgrades4 maintains

Recent actions · Sep 25–Oct 24 · 4 recorded

Price-target changes

30 days

○ Previous · ● Latest · common dollar scale

RBC CapitalOct 9 · prior Oct 8

$45.00 → $51.00+13.3%

$0$28.05$56.10

1 raises · 0 cuts · 0 unchanged · 0 without a comparable prior

How this is measured

Sep 25, 2026–Oct 24, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.

Outlook in Brief

The evidence, the remaining questions, and what comes next

What's improving

No recovery evidence is reported in the available driver assessments.

Still unresolved / key risks

Complete $750 million stock repurchase by end 2027Direct metric needs a verified mapping
Increase operating income to at least $251 million in Q1 2026Operating income: $248.414M
Maintain revenue near $2.575 billion in FY26Revenue: $628.69M

Next proof point

Oct 29, 2026

Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.

Review earnings

Bottom line

3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.

The dated weekly assessment and its assumptions are available in Read detailed Outlook.

Historical risk context

Observed price history; separate from operating scenarios

Price sensitivity

1.1%Typical daily move · historical

Downside history

-12.6%Maximum drawdown · trailing year

Read detailed Outlook Company context, assumptions & risks

Exelixis outlook in detail

The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.

Updated Oct 24, 2026

What kind of bet this is

This is a biotech company with a growing established drug franchise and a clinical-development component. The long-term thesis is intact, though the recent signal shifted from favorable to mildly favorable; confidence in the evidence is medium.

What's priced into Exelixis

The valuation evidence describes EXEL as cheap versus peers, while the overall priced-in tag is justified and fragility is low. The valuation model has low confidence, so the evidence does not support a clear claim about how much future execution the market already assumes.

What the fundamentals likely do

Near-term performance has been strong, with earnings beats in May and August and cabozantinib U.S. revenue rising from late 2025 to the second quarter of 2026. Management is advancing zanzalintinib, and the FDA accepted its application with a December 3, 2026 decision date; execution is mixed, while cabozantinib growth and capital allocation are on track. Near-term risk is assessed as quiet, but the next guidance update matters, and a recent litigation filing is a negative event.

What Exelixis hinges on

The multi-year view depends in part on continued cabozantinib growth and progress in zanzalintinib trials and regulatory review. A guidance cut would weaken the near-term case, while further strong results from healthcare peers could support sector momentum. Weaker employment data could also raise recession concerns and weigh on healthcare stocks.